CheckMate 057:纳武利尤单抗对比多西他赛治疗晚期非鳞NSCLC的健康相关生活质量与症状评估
CheckMate 057三期试验中,既往治疗的晚期非鳞非小细胞肺癌患者接受纳武利尤单抗或多西他赛。采用LCSS和EQ-5D评估患者报告结局,12周时症状改善率两组相似,但纳武利尤单抗组LCSS ASBI评分后续改善而多西他赛组恶化,组间差异在12、24、30和42周有统计学意义,且纳武利尤单抗组至首次HRQoL恶化时间更长。
要点
- 12周时LCSS ASBI症状改善率纳武利尤单抗17.8% vs 多西他赛19.7%,95%CI重叠。
- 纳武利尤单抗组LCSS ASBI评分后续改善,多西他赛组恶化,12/24/30/42周组间差异显著。
- 纳武利尤单抗组至首次HRQoL恶化时间较长,LCSS 3-IGI和EQ-5D VAS支持HRQoL改善。
核心结论
- 纳武利尤单抗二线治疗晚期非鳞NSCLC,相比多西他赛改善了疾病相关症状和总体健康状况。
研究设计与样本
- CheckMate 057三期试验,纳入既往治疗的晚期非鳞NSCLC患者,使用LCSS和EQ-5D评估患者报告结局。
主要发现
- 12周时疾病相关症状改善率(95%CI)纳武利尤单抗17.8%(13.6-22.7),多西他赛19.7%(15.2-24.7)。
- LCSS ASBI平均变化自基线数值上利于纳武利尤单抗,后续纳武利尤单抗组改善而多西他赛组恶化,12、24、30和42周组间差异有统计学意义。
- 至首次HRQoL恶化时间纳武利尤单抗组长于多西他赛组,LCSS 3-IGI和EQ-5D VAS及MMRM分析支持HRQoL改善。
临床怎么用
- 对于既往治疗的晚期非鳞NSCLC,纳武利尤单抗在生存获益之外可维持或改善HRQoL,支持其作为二线治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab, a programmed death-1 inhibitor, prolonged overall survival and had a favourable safety profile versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) in the phase III CheckMate 057 trial. AIM: To evaluate health-related quality of life (HRQoL) using patient-reported outcomes. METHODS: Disease-related symptoms and general health status were assessed using two validated patient-reported instruments, the Lung Cancer Symptom Scale (LCSS) and the European Quality of Life Five Dimensions (EQ-5D), respectively. The proportion of patients with disease-related symptom improvement at 12 weeks on the LCSS average symptom burden index (ASBI) was a secondary end-point. LCSS 3-item global index (3-IGI), EQ-5D utility index and EQ-5D visual analogue scale (VAS) scores were also determined. Mixed-effects model repeated measures (MMRM) and time to first deterioration analyses assessed longitudinal changes. RESULTS: Mean baseline LCSS ASBI scores were similar in both arms. By week 12, rates of disease-related improvement (95% confidence interval) were similar between nivolumab (17.8% [13.6-22.7]) and docetaxel (19.7% [15.2-24.7]); however, numerical differences in LCSS ASBI mean change from baseline favoured nivolumab. Subsequently, LCSS ASBI scores improved with nivolumab and worsened with docetaxel, with statistically significant between-arm differences at weeks 12, 24, 30 and 42. HRQoL improvements with nivolumab versus docetaxel were also supported by the LCSS 3-IGI, EQ-5D VAS and MMRM analysis. Time to first HRQoL deterioration was longer with nivolumab than with docetaxel. CONCLUSION: Nivolumab improved disease-related symptoms and overall health status versus docetaxel for second-line treatment of advanced non-squamous NSCLC. CLINICAL TRIAL REGISTRATION: NCT01673867.
引用
- Reck M, Brahmer J, Bennett B, et al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 2018. PMID: 30103096. doi:10.1016/j.ejca.2018.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。